A prospective, multicenter study of safety and immunogenicity of COVID-19 vaccination (CoronaVac, BBIBP-CorV, and WIBP-CorV) in hepatocellular carcinoma patients
Latest Information Update: 29 Sep 2022
Price :
$35 *
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 01 Nov 2022 Results published in the Journal of Medical Virology
- 29 Sep 2022 New trial record